Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia [PDF]
, 2017 Interactions between killer-immunoglobulin-like receptors (KIRs) and their HLA class I ligands are instrumental in natural killer (NK) cell regulation and protect normal tissue from NK cell attack.
Aurelius, J. +12 more
core +1 more source
FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia [PDF]
, 2004 Length mutations within the FLT3 gene (FLT3-LM) can be found in 23% of acute myeloid leukaemia (AML) and thus are the most frequent mutations in AML. FLT3-LM are highly correlated with AML with normal karyotype and other cytogenetic aberrations of the ...
Haferlach, Torsten +4 more
core +1 more source
Treatment of Relapsed Acute Myeloid Leukemia
Current Treatment Options in Oncology, 2020 Relapse is still a common scenario in acute myeloid leukemia (AML) treatment and occurs in 40–50% of younger and the great majority of elderly patients. The prognosis in relapsed AML patients is generally poor but depends largely on the timing of relapse
F. Thol, A. Ganser
semanticscholar +1 more source
Optimization of the indications for allogeneic stem cell transplantation in Acute Myeloid Leukemia based on interactive diagnostic strategies [PDF]
, 2011 The indications for allogeneic stem cell transplantation (SCT) in Acute Myeloid Leukemia (AML) represent a real challenge due to the clinical and genetic heterogeneity of the disorder.
Bacher, Ulrike +5 more
core
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
Blood, 2015 Acute myeloid leukemia (AML) can develop after an antecedent myeloid malignancy (secondary AML [s-AML]), after leukemogenic therapy (therapy-related AML [t-AML]), or without an identifiable prodrome or known exposure (de novo AML).
R. C. Lindsley +18 more
semanticscholar +1 more source
Immune escape and immunotherapy of acute myeloid leukemia.
Journal of Clinical Investigation, 2020 In spite of the recent approval of new promising targeted therapies, the clinical outcome of patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for additional and synergistic therapeutic rationales.
L. Vago, I. Gojo
semanticscholar +1 more source
Preleukemia: one name, many meanings. [PDF]
, 2017 Definition of preleukemia has evolved. It was first used to describe the myelodysplastic syndrome (MDS) with a propensity to progress to acute myeloid leukemia (AML). Individuals with germline mutations of either RUNX1, CEBPA, or GATA2 can also be called
Koeffler, HP, Leong, G
core
Biomarkers of leukemia risk: benzene as a model. [PDF]
, 1998 Although relatively rare, leukemias place a considerable financial burden on society and cause psychologic trauma to many families. Leukemia is the most common cancer in children.
Smith, MT, Zhang, L
core +3 more sources
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.
Cancer Discovery, 2020 The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in the past few years, driven largely by translational research into its genomic landscape and an improved understanding of mechanisms of resistance to conventional ...
N. Short +6 more
semanticscholar +1 more source
Role of vitamin A/retinoic acid in regulation of embryonic and adult hematopoiesis [PDF]
, 2017 Vitamin A is an essential micronutrient throughout life. Its physiologically active metabolite retinoic acid (RA), acting through nuclear retinoic acid receptors (RARs), is a potent regulator of patterning during embryonic development, as well as being ...
Adamo +23 more
core +4 more sources